Goldman Sachs Group Inc Avrobio, Inc. Transaction History

Goldman Sachs Group Inc

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 May 14, 2024	SELL	$0.64 - $0.91 $445,923 - $634,047	-696,756 Reduced 98.57%	10,082 $7,000
Q4 2022 Feb 13, 2023	SELL	$0.64 - $0.91 $445,923 - $634,047	-696,756 Reduced 98.57%	10,082 $7,000
Q3 2022 May 14, 2024	BUY	$0.68 - $1.11 $379,706 - $619,815	558,392 Added 376.16%	706,838 $454,000
Q3 2022 Nov 10, 2022	BUY	$0.68 - $1.11 $379,706 - $619,815	558,392 Added 376.16%	706,838 $0
Q2 2022 May 14, 2024	BUY	$0.75 - $1.33 $111,334 - $197,433	148,446 New	148,446 $136,000
Q2 2022 Aug 15, 2022	SELL	$0.75 - $1.33 $92,477 - $163,992	-123,303 Reduced 45.37%	148,446 $136,000
Q1 2022 May 16, 2022	SELL	$1.29 - $4.04 $1.43 Million - $4.48 Million	-1,110,009 Reduced 80.33%	271,749 $359,000
Q4 2021 Feb 14, 2022	BUY	$3.45 - $6.05 $3.28 Million - $5.75 Million	949,620 Added 219.75%	1,381,758 $5.32 Million
Q3 2021 Nov 10, 2021	BUY	$5.53 - $9.28 $2.39 Million - $4.01 Million	432,138 New	432,138 $2.41 Million

559K

Ticker AVRO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,773,900
Description
AVROBIO, Inc., a clinical-stage gene therapy company, develops ex vivo lentiviral-based gene therapies to treat rare diseases following a single dose worldwide. Its gene therapies employ hematopoietic stem cells that are collected from patients and modified with a lentiviral vector to insert functional copies of the gene that is defective in the...

Get notified when there are updates to the investment portfolio of Goldman Sachs Group Inc, based on Form 13F filings with the SEC.

Stay updated on Goldman Sachs Group Inc with notifications on news.